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Introduction
To ensure the accurate inheritance of genetic information, cells 
must not only replicate their DNA but also duplicate the struc-
ture of chromatin and its higher order packaging during S phase 
of the cell cycle. Alteration of these processes can have devas-
tating consequences leading to DNA damage and genomic in-
stability, as observed in cancer cells (Venkitaraman, 2005). 
Whereas transmission of DNA methylation patterns can be eas-
ily explained by coupling enzymatic modifi  cation to the semi-
conservative DNA replication process (Leonhardt et al., 1992; 
Chuang et al., 1997), it is still unclear how the epigenetic marks 
and higher order structures of chromatin are maintained during 
DNA replication and faithfully transmitted.
PR-Set7 (also known as SET8) is a single polypeptide with 
an evolutionary conserved SET domain that specifi  cally cata-
lyzes monomethylation of histone H4-K20 (H4-K20me1; Fang 
et al., 2002; Nishioka et al., 2002; Couture et al., 2005; Xiao et al., 
2005), whereas dimethylation (H4-K20me2) and trimethylation 
(H4-K20me3) of the same lysine are triggered by several other 
histone methyltransferases, including Suv420h1/2 (Schotta et al., 
2004), NSD1 (Rayasam et al., 2003), and Ash1 (Beisel et al., 
2002). H4-K20 trimethylation (H4-K20me3) selectively marks 
constitutive pericentromeric heterochromatin (Schotta et al., 
2004) and imprinting control regions (Delaval et al., 2007), 
whereas mono- and dimethylation are broadly distributed but 
principally enriched in euchromatin regions (Nishioka et al., 
2002; Karachentsev et al., 2005). Although the biological func-
tion of H4-K20me remains poorly understood, several studies 
have suggested that H4-K20me2 is involved in the guidance of 
DNA repair proteins to DNA strand breaks (Sanders et al., 2004; 
Botuyan et al., 2006), whereas H4-K20me1 is associated with 
chromatin condensation processes (Trojer et al., 2007). Further-
more, changes in H4-K20me3 patterns are frequently observed 
in human cancers (Fraga et al., 2005), suggesting that the epigen-
etic signal achieved with this methyl residue can affect important 
chromatin-templated processes with far-reaching consequences 
for normal and neoplastic development.
As part of the initial characterization of PR-Set7 func-
tions, its levels in HeLa cells were found to be cell cycle regu-
lated with a peak during M phase (Rice et al., 2002). Furthermore, 
PR-Set7 becomes phosphorylated at the G2/M transition 
(Georgi et al., 2002) and remains associated with chromosomes 
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during mitosis (Rice et al., 2002). Collectively, these observa-
tions suggested that this enzyme might be involved in some as-
pects of cell division control. Consistent with this hypothesis, 
inactivation of the Drosophila melanogaster PR-Set7 orthologue 
causes defective mitotic progression and activation of DNA 
damage checkpoints in highly dividing cells of larval tissues, 
including imaginal disc cells and third instar larval neuro-
blasts (Karachentsev et al., 2005; Sakaguchi and Steward, 2007). 
Conversely, up-regulation of mammalian PR-Set7 expression 
upon loss of the transcriptional regulator HCF-1 leads to im-
proper mitotic H4-K20 methylation levels and cytokinesis de-
fects in HeLa cells (Julien and Herr, 2004). However, it remained 
unclear whether these mitotic defects were the effect of PR-Set7 
functions in the mitotic process or whether they were the end 
point of cellular alterations generated before the onset of mito-
sis, thereby raising the question of PR-Set7 functions during the 
different phases of the cell cycle.
In this paper, we study the functions of human PR-Set7. 
Our results show that PR-Set7 regulates cell cycle progression 
by playing a key role during S phase. PR-Set7 associates with sites 
of DNA synthesis and regulates replication-fork progression. 
Inhibition of its catalytic activity causes improper DNA replica-
tion and loss of H4-K20 mono- and trimethylation. These defects 
are associated with massive induction of DNA breaks that leads 
to a p53-dependent DNA damage response to avoid entry into 
mitosis and aberrant chromosome behavior. Collectively, our re-
sults establish that PR-Set7–dependent lysine methylation is an 
essential posttranslational modifi  cation that contributes to ge-
nome replication and stability through S phase.
Results
PR-Set7 localizes with sites of 
DNA synthesis
As previously described by others in HeLa cells (Rice et al., 
2002), we observed in both human osteosarcoma U2OS cells 
and human normal fibroblasts (HNFs) that PR-Set7 protein 
levels fl  uctuate during the cell cycle with a peak during M phase 
(Fig. S1 A, available at http://www.jcb.org/cgi/content/full/
jcb.200706179/DC1). During G1 and S phases, PR-Set7 protein 
levels were low and almost undetectable using conventional 
immunostaining on fi  xed cells (Rice et al., 2002; and unpub-
lished data). This is largely caused by a high turnover of the 
PR-Set7 proteins driven by a proteasome-dependent degrada-
tion process (unpublished data). Accordingly, short incuba-
tion (1 h) of U20S cells with the proteasome inhibitor MG132 
rendered endogenous PR-Set7 easily detectable by immuno-
fl  uorescence in all asynchronously growing cells, with  35% 
showing a small, punctated nuclear staining (Fig. 1 A, left). 
Importantly, transient transfection of an HA epitope–tagged 
PR-Set7 in U2OS cells resulted in the same punctated pattern 
(Fig. S1 B), whereas it was not observed in cells depleted for 
PR-Set7 by siRNA treatment (not depicted). Because PR-Set7 
has been described as a chromatin-associated protein, we checked 
whether these PR-Set7 foci colocalized with previously de-
scribed chromatin/DNA foci (Baus et al., 2003; Peters et al., 
2003). Strikingly, they did not colocalize with HP1 heterochro-
matin foci or with γ-H2A.X DNA damage foci after bleomycin 
treatment (Fig. 1 A, merged panels). In contrast, PR-Set7 foci 
colocalized with the sites of DNA synthesis detected by a short 
pulse (10 min) of BrdU incorporation (Fig. 1 B, merged panel). 
Accordingly, coimmunostaining was also detected with the pro-
liferating nuclear antigen A and the DNA polymerase epsilon, 
two components of the replication machinery (Fig. 1 C, merged 
panels). This colocalization was observed at all stages of S phase 
based on the size and nuclear localization of BrdU-positive rep-
lication foci (unpublished data). Collectively, these results sug-
gested that PR-Set7 might be important for DNA replication 
and S-phase progression.
PR-Set7–depleted cells display improper 
S-phase progression
To investigate whether PR-Set7 plays a role in DNA replication, 
we used a small hairpin RNA (shRNA)–expressing retroviral 
vector to stably express a PR-Set7 shRNA designed to silence 
PR-Set7 expression. Specifi  city of the PR-Set7 shRNA (shPR7) 
was verifi  ed by an shRNA-based protein replacement approach 
(Julien and Herr, 2003) in which an HA epitope–tagged PR-Set7 
protein resistant to shPR7 treatment was expressed at physio-
logical levels. As shown in Fig. 2 A, expression of the PR-Set7–
specifi   c shRNA (shPR7) but not of an irrelevant luciferase-specifi  c 
shRNA (shLuc) led to the successful depletion of PR-Set7 2 d 
after cell infection, whereas the β-actin protein level was not af-
fected (middle and bottom; compare lane 1 with lane 2). As ex-
pected, ectopic expression of the shRNA-resistant wild-type 
PR-Set7 protein was suffi  cient to rescue PR-Set7 expression in 
shPR7-expressing cells (Fig. 2 A, lanes 3 and 4). In the following 
experiments, we used these shRNA-resistant wild-type PR-Set7 
protein U2OS cells (U2OSSR) as a control to ascertain that the 
phenotype induced by shPR7 was specifi  c of PR-Set7 depletion.
We fi rst compared the proliferation rates of U2OS cells 
expressing either shLuc or shPR7 and U2SOSR cells expressing 
shPR7. As shown in Fig. 2 B, shPR7 U2OS cells displayed a 
marked decrease in cell proliferation soon after shRNA treat-
ment. In contrast, shPR7 U2OSSR cells continued to proliferate 
at nearly the same rate as shLuc U2OS cells. We next analyzed 
the cell cycle profi  les of the three cell lines at days 2, 3, and 4 after 
shRNA expression by measuring their DNA content. The results 
are shown in Fig. 2 C. In contrast to shLuc U2OS (Fig. 2 C; a, d, 
and g) and shPR7 U2OSSR cells (Fig. 2 C; c, f, and i), shPR7 U2OS 
cells (Fig. 2 C; b, e, and h) started to accumulate in S phase 
(from 26 to 56%) 3 d after shRNA expression. Importantly, a 
similar phenotype was also observed with normal and trans-
formed human fi  broblasts (see Fig. 5), suggesting that this re-
sult is not cell type specifi  c. Furthermore, 24 h after the onset of 
the S-phase accumulation, a signifi  cant increase in the percent-
age of cells in the G2/M stage was detected (20 ± 8%), suggesting 
that some PR-Set7–depleted cells were still able to progress 
through and exit S phase, albeit slower than control cells (Fig. 2 C, 
day 4). Importantly, none of these cells were immunostained by 
an antibody against the mitotic marker phosphohistone H3 S10 
(unpublished data), indicating that PR-Set7–depleted cells that 
had exited S phase were likely arrested in G2. Thus, consistent 
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PR-Set7 silencing leads to a defective S-phase progression in 
mammalian cells.
Other studies have shown that human PR-Set7 also asso-
ciates with mitotic chromosomes (Rice et al., 2002), raising the 
possibility that PR-Set7 also plays a role during M phase of the 
cell cycle. To determine whether the improper S-phase progres-
sion of PR-Set7–depleted cells resulted from S-phase altera-
tions or from alterations that occurred during the previous 
M phase, we synchronized U2OS and U2OSSR cells at the G1/S 
border 36 h after shRNA expression. At this time, shPR7 U2OS 
Figure 1.  PR-Set7 localizes at sites of DNA synthesis. 
(A) Nuclei of asynchronously growing U2OS cells 
treated for 1 h with 15 μM MG132 to inhibit protea-
some degradation and permeabilized for 10 min with 
0.5% Triton X-100 to remove soluble nuclear and 
cytoplasmic proteins before PFA ﬁ  xation. Cells were 
stained with anti–PR-Set7 (a and d), anti–γ-H2A.X (b), 
or anti-HP1γ (e) antibodies. Staining with anti–PR-Set7 
(d) and anti–γ-H2A.X (b) was performed in U2OS 
cells treated with both MG132 and 25 μg/ml bleo-
mycin for 1 h before ﬁ  xation. (B) Nuclei of U2OS cells 
stained with anti–PR-Set7 (a) and anti-BrdU (b) anti-
bodies. Cells were pulse labeled for 10 min with BrdU 
and treated as described in A before ﬁ  xation. (C) Nu-
clei of asynchronously growing U2OS cells treated as 
described in A and stained with anti–PR-Set7 (a and d), 
anti–proliferating nuclear antigen A (b), or anti-DNA 
polymerase ε (e) antibodies. Bars, 5 μm.JCB • VOLUME 179 • NUMBER 7 • 2007  1416
Figure 2.  PR-Set7–depleted cells display improper S-phase progression. (A) Immunoblot analysis of U2OS cells (lanes 1 and 2) and U2OS cells synthesizing 
the PR-Set7SR recombinant protein (lanes 3 and 4) 2 d after either luciferase (lanes 1 and 3) or PR-Set7 (lanes 2 and 4) shRNA expression. shLuc for lucifer-
ase shRNA and shPR7 for PR-Set7 shRNA. The PR-Set7SR protein is visualized alone (HA tag antibody; top) or together with endogenous PR-Set7 proteins 
(middle). β-actin (bottom) is used as a loading control. Resistance to shPR7 treatment is given by ﬁ  ve silent mutations in the mRNA sequence targeted by 
shPR7. (B) Proliferation rates of U2OS cells expressing either luciferase (shLuc) or PR-Set7 (shPR-Set7) shRNA and U2OS cells synthesizing PR-Set7SR 
(U2OSSR) and expressing PR-Set7 shRNA. The proliferation rate of U2OSSR cells expressing luciferase shRNA is similar to shluc U2OS cells (not depicted). PR-SET7 FUNCTIONS IN DNA REPLICATION • TARDAT ET AL. 1417
cells still contained PR-Set7, as shown in Fig. 2 D (top left). 20 h 
later, once PR-Set7 was effi  ciently depleted (Fig.  2 D, top right), 
cells were released and pulse labeled with BrdU for 1 h at the indi-
cated times to follow their progression through S phase. The results 
are shown in Fig. 2 D (bottom). 4 h after release, BrdU incorpor-
ation and DNA content of shLuc U2OS, shPR7 U2OS, and 
shPR7 U2OSSR indicated that entry into S phase was similar in 
the three cell populations. However shLuc U2OS and shPR7 
U2OSSR cells underwent progression through S phase over an 
 10-h time period, with  70% of cells emerging in G2/M 
stage (Fig. 2 D, bottom; left and right), whereas shPR7 U2OS 
cells failed to complete S phase for the duration of the experiment 
(Fig. 2 D, bottom; middle). These results indicate that accurate 
completion of DNA replication is indeed directly dependent on 
PR-Set7 functions during S phase.
PR-Set7 silencing leads to massive 
DNA strand breaks during S phase and 
activation of a DNA damage response
Improper S-phase progression followed by a G2-phase arrest in 
PR-Set7–depleted cells led us to hypothesize that these cells had 
activated their DNA damage checkpoint. As shown in Fig. 3 A, 
alkaline comet assays, which monitor mainly single-strand breaks 
and alkali labile sites, revealed extensive DNA strand breaks in 
U20S cells 3 d after shPR7 expression. Close to 80% of the PR-
Set7–depleted U2OS cells displayed comets with a tail moment 
greater than fi  ve (Fig. 3 B), whereas no signifi  cant signature of 
damage was observed in control cells (shLuc-treated U2OS and 
shPR7 U2OSSR cells). Strikingly, spontaneous DNA strand 
breakage upon PR-Set7 silencing led to a robust DNA damage 
response. As shown in Fig. 3 C, the molecular signature of this 
response was easily detectable by immunoblotting in shPR7 U2OS 
cellular extracts with the presence of the activated/phosphorylated 
forms of the DNA damage kinases ataxia telangiectasia related 
(ATR) and ataxia telangiectasia mutated (ATM) and their phos-
phorylated targets CHK1 (phosphoserine 345), H2A.X (γ-H2A.X), 
and p53 (phosphoserine 15). A p53-dependent response was also 
activated in these cells, as indicated by the sustained up-regulation 
of the cyclin-dependent kinase inhibitor p21
Waf1 (Fig. 3 C), a 
transcriptional target of p53 implicated in the maintenance of G2 
arrest after DNA damage (Taylor and Stark, 2001). Importantly, 
this activation of the DNA damage signaling cascade was not 
detected in cellular extracts prepared from shLuc U2OS cells 
and shPR7 U2OSSR control cells (Fig. 3 C).
We next asked whether the DNA breaks that appeared 
upon PR-Set7 silencing occurred during S phase. 2 d after shLuc 
or shPR7 expression, U2OS and U2OSSR cells were synchro-
nized at the G1/S boundary as described in Fig. 2 D and were re-
leased with fresh BrdU-containing medium 24 h later. Cells were 
subsequently stained with α-BrdU antiserum (to identify cells that 
had entered S phase) and with an antiserum against the phosphory-
lated form of histone H2A.X (γ-H2A.X). The results are shown 
in Fig. 3 D. As expected, only  3% of shLuc U2OS cells and 
 7% of shPR7 U2OSSR cells displayed both BrdU and γ-H2A.
X staining during S-phase progression (Fig. 3 D). In contrast, 
whereas no γ-H2A.X staining was detected in shPR7 U2OS 
cells before release from the G1/S block, an intense γ-H2A.X 
immunostaining was observed in S phase–progressing cells, 
with up to 65% of BrdU-positive cells showing γ-H2A.X staining 
5 h after their release (Fig. 3 D, top and bottom). Interestingly, 
digital sectioning images of asynchronous shPR7 U2OS cells 
incubated with BrdU for 10 min to detect active replication foci 
showed that a signifi  cant fraction of BrdU-positive foci colocal-
ized with DNA damage foci (Fig. 3 E). A partial colocalization 
may lie in the fact that the appearance of DNA damage at repli-
cation foci rapidly causes the arrest of replication (Sancar et al., 
2004), thereby preventing the incorporation of BrdU. Collectively, 
our results strongly suggest that the absence of PR-Set7 causes 
DNA breaks at replication sites, thereby leading to a DNA dam-
age response characterized by activation of the ATM and ATR 
kinase–mediated pathways.
PR-Set7 regulates replication fork activity
The appearance of DNA breaks during S phase of PR-Set7–
depleted cells could refl  ect some defects in replication fork 
activity. To adress this question, we monitored DNA replication 
dynamics at the level of individual DNA molecules by DNA 
combing experiments (Michalet et al., 1997; Pasero et al., 2002). 
3 d after shLuc and shPR7 expression, we measured the velocity 
of replication forks by pulse labeling shRNA-treated cells con-
secutively with the thymidine analogues iododeoxyuridine (IdU) 
and chlorodeoxyuridine (CldU). Staining of combed DNA with 
anti-IdU and -CldU antibodies identifi  ed ongoing forks either as 
a stretch of IdU framed by CldU labeling or IdU label followed 
by a single CldU label. Representative examples of immuno-
staining are shown in Fig. S2 A (available at http://www.jcb.org/
cgi/content/full/jcb.200706179/DC1). As shown in Fig. 4 A, 
quantifi  cation of the length of IdU/CldU signals indicated that 
the rates of elongation were dramatically reduced in PR-Set7–
depleted cells (mean speed of 578 bp/min) compared with con-
trols (750 bp/min and 892 bp/min in shPR7-treated U2OSSR cells 
and shLuc-treated U2OS cells, respectively), suggesting that 
replication fork velocity is impaired in the absence of PR-Set7.
We next examined the rate of initiation by measuring the 
density of replicated tracks in shLuc and shPR7 shRNA– treated 
cells, which entered into S phase synchronously. After pulse la-
beling cells with BrdU for 15 min, replicated tracks were de-
tected with a BrdU antibody, and DNA fi  bers were counterstained 
with an antiguanosine antibody as shown in Fig. S2 B. Consistent 
with a reduction in fork velocity upon PR-Set7 depletion (Fig. 4 A), 
At the indicated times, cells were harvested and counted from duplicate plates, and the results were averaged. The number of cells is represented on a loga-
rithmic scale. (C) Cell cycle proﬁ  les of shLuc (a, d, and g) or shPR7 (b, e, and h) U2OS cells and shPR7 U2OSSR cells (c, f, and i). At the times indicated, 
cells were labeled with BrdU for 1 h before harvest and were stained with an anti-BrdU antibody and 7AAD. Only histograms of DNA ﬂ  uorescence are 
shown. (D, top) Western blot analysis for PR-Set7 and β-actin levels in U2OS and U2OSSR cells arrested at G1/S stage by thymidine block 2 d after shRNA 
expression and released into S phase 20 h later. (bottom) Cell cycle distribution of shLuc (left) or shPR7 U2OS cells (middle), and shPR7 U2OSSR cell (right) 
release into S phase from a thymidine block (0 h) and pulse labeled for 1 h with BrdU at the times indicated below each panel. The percentage of cells in 
each stage of the cell cycle was monitored by measuring BrdU incorporation and DNA content with a ﬂ  ow cytometer in three independent experiments.JCB • VOLUME 179 • NUMBER 7 • 2007  1418
Figure 3.  PR-Set7 silencing causes massive DNA breaks during S phase, which leads to activation of the DNA damage checkpoint. (A) Representative com-
ets of shLuc and shPR7 U2OS cells and shPR7 U2OSSR cells. Alkaline comet analysis was performed 3 d after shRNA expression. At least 200 randomly 
chosen comets were captured. (B) Distribution of cells with different comet tail moments and quantiﬁ  cation of the number of cells with comet tail moments 
greater than ﬁ  ve (inset) are illustrated for each cell line. The tail moment and distribution were scored from 200 cells/slide by using Comet Imager 1.2.10 
software. (C) Immunoblot analysis of the total levels of p53 and P21 and the levels of phosphorylation of ATM, ATR, CHK1, H2A.X, and p53 in U2OS 
(lanes 1 and 2) and U2OSSR (lane 3) cells 3 d after either shLuc (lane 1) or shPR7 (lanes 2 and 3) expression. (D) Immunoﬂ  uorescence of BrdU (a, c, and e) 
and γ-H2A.X (b, d, and f) in shLuc and shPR7 U2OS cells and shPR7 U2OSSR cells 3 h after release from a thymidine block. (bottom) Quantiﬁ  cation of dou-
ble BrdU and γ-H2A.X–positive cells in shRNA-expressing U2OS and U2OSSR cell lines. Cells were harvested and analyzed by immunoﬂ  uorescence at the 
times indicated. The percentages of double BrdU and γ-H2A.X–positive cells were obtained by counting 300 cells from three independent experiments. 
Error bars represent SD. (E) Images of asynchronous shPR7 U2OS nuclei acquired with Apotome microscopy 3 d after shRNA expression. After BrdU 
incorporation for 10 min, cells were stained with anti-BrdU antibody to detect active replication foci (a) and anti-53BP1 antibody to detect DNA damage foci (b). 
The merged picture (c) showed a partial but signiﬁ  cant overlay. Bars, 5 μm.PR-SET7 FUNCTIONS IN DNA REPLICATION • TARDAT ET AL. 1419
the length of the replicated tracks was shorter in shPR7 U2OS 
cells than in shLuc U2OS and shPR7 U2OSSR cells (Fig. 4 B). 
Furthermore, the number of replicated tracks was severely re-
duced in shPR7 U2OS cells (Fig. 4 C), and, accordingly, the 
mean distance between these tracks was longer in these cells 
(Fig. 4 D). Thus, in addition to a reduction in fork velocity, PR-
Set7–depleted cells display a decrease in the density of active 
replication forks.
These results were surprising because a decrease in fork 
velocity is often compensated by an increase in replication fork 
density (Anglana et al., 2003). We assumed that this might re-
fl  ect the inhibition of late replication origins by the ATR and 
ATM kinase pathways in response to DNA damage (Sancar et al., 
2004). To test this hypothesis, replication fork activity (Fig. 4, 
B–D) and cell cycle progression (Fig. 4 E) were analyzed in 
shPR7 U2OS cells that were treated for 5 h with 10 mM caffeine 
(an inhibitor of ATM and ATR kinases). Although the length of 
replicated tracks remained severely reduced in these caffeine-
treated shPR7 U2OS cells (Fig. 4 B, bottom), the density of their 
active replication forks was largely increased (Fig. 4, C [bar 4] 
and D), and they were then able to bypass S-phase arrest upon 
PR-Set7 depletion (Fig. 4 E). Thus, these results support a sce-
nario in which the absence of PR-Set7 at replication foci impairs 
the progression of the replication machinery, leading to DNA 
breaks and activation of a DNA damage response that delays 
S-phase progression by regulating the origin-fi  ring timing.
The p53 response induced by DNA 
damage in PR-Set7–depleted cells is 
required to prevent aberrant mitotic 
chromosome behavior
Inactivation of the Drosophila PR-Set7 orthologue also causes 
an activation of a DNA damage response in neuroblasts of the 
third instar larval brains (Sakaguchi and Steward, 2007). However, 
in contrast to our results, this activation is associated with extensive 
mitotic defects, including improper mitotic chromosome struc-
ture and progression (Karachentsev et al., 2005; Sakaguchi and 
Steward, 2007). In our case, we did not observe signifi  cant al-
terations of these mitotic events in shPR7 U2OS cells (unpub-
lished data). This might refl  ect the fact that the Drosophila p53 
orthologue does not possess the growth arrest functions like 
its mammalian counterpart (De Nooij and Hariharan, 1995; 
Sogame et al., 2003).
To address this point, we investigated whether human 
p53 was required to prevent the onset of mitosis in PR-Set7–
depleted cells that were able to exit S phase with DNA damage. 
Thus, shRNA-mediated depletion of PR-Set7 was performed in 
HNFs or in the same cells expressing the human papillomavirus 
oncoprotein E6 (HNFE6), which targets p53 for degradation 
(Scheffner et al., 1993). Although E6 has targets other than p53, 
HNFE6 cells are commonly used as a human cellular model de-
fi  cient for p53 functions (Baus et al., 2003; Mallette et al., 2007). 
As shown in Fig. 5 A, cell cycle profi  le analyses showed that 
both shPR7 HNF and shPR7 HNFE6 cells gradually accumu-
lated in S phase and then in the G2/M stage 3 d after shRNA 
expression. Consistent with our data in U20S cells, none of the 
shPR7 HNF cells with DNA damage had entered into mitosis, 
as indicated by the fact that we did not detect fl  uorescent co-
immunostaining of these cells probed with the DNA damage 
marker γ-H2A.X and the mitotic marker phosphohistone H3-S10 
(unpublished data). In contrast, this costaining was readily ob-
served in  90% of shPR7 HNFE6 mitotic cells, as shown in Fig. 
5 B. Strikingly, these cells displayed abnormal mitotic chromo-
some morphology (Fig. 5 B).
To document this observation, we prepared chromosome 
spreads after a 30-min colchicine treatment and hypotonic 
shock. As illustrated in Fig. 5 C, shLuc mitotic cells showed 
clearly defi  ned sister chromatids (panel a). In contrast, most of 
chromosome spreads of shPR7 mitotic HNFE6 showed either 
defective chromosome condensation ( 80%) as shown in Fig. 5 
(C, b and c) or condensed chromosomes ( 20%) but with a 
signifi  cant number of aberrations, including chromosome breaks 
(Fig. 5 C; d, d-1, d-2, and d-3) and sister chromatid fusion 
(Fig. 5 C; d and d-4). Conspicuously, such mitotic defects are 
reminiscent of those observed in Drosophila PR-Set7–depleted 
neuroblasts (Sakaguchi and Steward, 2007). These data illustrate 
the importance of the DNA damage–induced p53 re  sponse to 
prevent abnormal chromosome behavior upon PR-Set7 depletion 
in human cells.
PR-Set7 depletion in U2OS cells is 
associated with reduced levels of H4-K20 
mono- and trimethylation
To gain insights into the mechanisms by which PR-Set7 regu-
lates DNA replication and genome stability, we examined the 
levels of H4-K20 methylation in PR-Set7–depleted cells dis-
playing improper S-phase progression. 3 d after shRNA expres-
sion, total histones of U2OS and U2OSSR cells were acid 
extracted and subjected to immunoblot analysis with the differ-
ent antimethylated H4-K20 antibodies. The results are shown in 
Fig. 6 A. The levels of the three methyl marks were similar be-
tween shLuc U2OS and shPR7 U2OSSR cells (Fig. 6 A). In con-
trast, the levels of H4-K20me1 as well as of H4-K20me3 were 
strongly reduced in shPR7 U2OS cells, suggesting that PR-Set7 
plays a key role in the maintenance of both H4-K20 mono- and 
trimethyl marks during S phase. For H4-K20me2, we observed 
only a slight reduction in shPR7 U2OS cells (Fig. 6 A), suggest-
ing that changes in H4-K20me2 levels are not associated with 
the DNA replication defects described here. Consistent with the 
preservation of H4-K20me2 in PR-Set7–depleted U2OS cells, 
p53-binding protein 1 (53BP1), which associates primarily with 
H4-K20me2 in response to DNA damage (Botuyan et al., 2006), 
was still colocalized with spontaneous as well as irradiation-
induced DNA damage foci (Fig. S3, available at http://www.jcb
.org/cgi/content/full/jcb.200706179/DC1).
Repeated siRNA-mediated depletion of PR-Set7 in HeLa 
cells was reported by others to result in the disappearance of 
H4-K20me2 (Botuyan et al., 2006). Consistent with this study,   
we also observed a clear reduction in H4-K20me2 levels in 
shPR7-treated HeLa cells, but at least 2 d after the decrease of 
H4-K20me1 and H4-K20me3 (Fig. S4, available at http://www
.jcb.org/cgi/content/full/jcb.200706179/DC1). However, in strike 
contrast with our results in U2OS cells and normal fi  broblasts, HeLa 
cells continue to proliferate after PR-Set7 depletion (Fig. S4; JCB • VOLUME 179 • NUMBER 7 • 2007  1420
Figure 4.  PR-Set7 regulates replication fork activity. (A) Distribution of fork velocity from 200 ongoing replication forks in shLuc or shPR7 U2OS cells and 
in shPR7 U2OSSR cells (left). Squares represent the quartiles (25% of the fork rate values smaller and higher than the median value), and the deviations 
show the smallest and greatest fork rate values. Mean fork rates with SDs are indicated for each sample (right). P < 0.0002 as determined by the nonpara-
metric test of Mann-Whitney. (B) Distribution of replicated track lengths after 30 min of BrdU incorporation in shLuc U2OS (top), shPR7 U2OS and U2OSSR 
cells (middle), and shPR7 U2OS treated with caffeine for 5 h (bottom). Mean lengths with SDs are indicated for each panel. Results were averaged from 
ﬁ  ve independent experiments. (C) Quantiﬁ  cation of active replication sites for 10 Mb DNA in BrdU-positive shLuc (bar 1) or shPR7 (bar 2) U2OS cells, 
BrdU-positive shPR7 U2OSSR cells (bar 3), and BrdU-positive shPR7 U2OS cells treated with caffeine for 5 h (bar 4). The number of active replication sites was 
obtained by counting the number of individual BrdU tracks for 10 Mb DNA 3 d after shRNA expression in ﬁ  ve independent DNA combing experiments. PR-SET7 FUNCTIONS IN DNA REPLICATION • TARDAT ET AL. 1421
Julien and Herr, 2004). This continued cell cycle progression 
upon PR-Set7 depletion likely refl  ects the fact that the genetic 
and growth properties of HeLa cells are highly altered by onco-
genic transformation. Therefore, we assume that the reduction 
of H4-K20me2 levels is a late and indirect event that can be ob-
served only in cells that continue to proliferate upon PR-Set7 
depletion. Thus, these results suggest that the DNA replication 
defects and DNA breaks observed in PR-Set7–depleted U2OS 
cells are primarily associated with a global loss of the K20me1 
and K20me3 methylated forms of histone H4.
PR-Set7–mediated lysine methylation 
is essential for S-phase progression 
and genomic stability
To further demonstrate that loss of the histone methyltransferase 
activity of PR-Set7 is indeed the key event that causes defective 
DNA replication and genomic instability during S phase, we ex-
amined the ability of shRNA-resistant PR-Set7 (PR-Set7SR) mu-
tants to rescue the PR-Set7 loss of function phenotype. Fig. 6 B 
shows the structure of the different PR-Set7SR mutants tested. 
Among them, only PR-Set7SR/∆141–322 deleted for the SET do-
main and PR-Set7SR/R265G, which contains an arginine to glycine 
substitution at position 265 within the entire SET domain, lack 
PR-Set7 methyltransferase activity (Nishioka et al., 2002).
The PR-Set7SR mutants were stably expressed in U2OS 
cells and infected with either shLuc or shPR7 retrovirus. 4 d after 
shRNA expression, we monitored (1) defective S-phase progres-
sion by measuring the levels of BrdU incorporation and DNA 
content by fl  ow cytometry and (2) DNA damage by immunofl  uor-
esence with γ-H2A.X staining. The results are shown in Fig. 6 
(C and D, respectively). Importantly, the different PR-Set7 mu-
tants themselves did not induce defective cell cycle progression 
and DNA breaks compared with untransfected cells (unpublished 
data). As expected, PR-Set7 inhibition led to an accumulation of 
cells in S and G2/M stages associated with DNA breaks (Fig. 6, 
C and D). Analysis of the different PR-Set7SR mutants reveals that 
PR-Set7 methyltransferase activity is essential to preserve ge-
nome stability and proper DNA replication. Wild-type PR-Set7SR 
as well as PR-Set7SR/∆1–30, PR-Set7SR/∆37–50, and PR-Set7SR/∆51–140 
(Fig. 6 D, bars 2–5) were generally successful in rescuing both 
normal S-phase progression (Fig. 6 D) and genome stability (Fig. 
6 D), whereas PR-Set7SR/∆141–322 and PR-Set7SR/R265G were not 
(Fig. 6 D, bars 6 and 7). Collectively, these results indicate that 
PR-Set7–mediated lysine methylation, likely H4-K20me, is es-
sential for the accurate completion of DNA replication and for 
preservation of genome integrity through S phase.
Discussion
In this study, we provide evidence that the histone H4-K20 methy  l-
transferase PR-Set7 plays a key role during S phase in normal 
as well as in transformed human cells. Consistent with a role in 
DNA replication and in the maintenance of chromosome integ-
rity during S phase, we have shown that PR-Set7 localizes with 
sites of DNA synthesis and regulates the bulk of histone H4-K20 
methylation. Inhibition of PR-Set7 by shRNA causes (1) altera-
tions in the number and velocity of active replication forks and 
(2) massive induction of DNA strand breakage followed by a ro-
bust DNA damage response. This DNA damage response in-
cludes the activation of ATM and ATR kinase–mediated pathways, 
which leads to a p53-mediated growth arrest in G2 to avoid aber-
rant chromosome behavior after improper DNA replication.
To characterize the PR-Set7 loss of function phenotype in 
mammalian cells, we used shRNA viral vectors to silence PR-
Set7 expression. The main limitation of this approach is the off-
target effects of the shRNA sequences (for review see Cullen, 
2006). Therefore, we created shRNA-resistant wild-type PR-
Set7 molecules in U2OS cells and sucessfully rescued all as-
pects of the PR-Set7 loss of function phenotype. Finally, the use 
of mutant shRNA-resistant PR-Set7 molecules revealed that the 
PR-Set7 methyltransferase activity was essential for genome 
replication and stability through S phase.
Regulation of H4-K20 methylation 
levels by PR-Set7
In mammalian cells, mono- and trimethylation of H4-K20 ap-
pear relatively stable during the cell cycle, whereas dimethyl-
ation follows a cyclic pattern with maximum levels in S phase, 
suggesting that H4-K20me1 and H4-K20me3 are regulated dif-
ferently than the dimethyl mark (Fang et al., 2002; Karachentsev 
et al., 2007). Accordingly, our results in U2OS cells indicate 
that PR-Set7 functions during S phase are important for the 
maintenance of H4-K20me1 and H4-K20me3 but not for H4-
K20me2 (Fig. 6). A role for PR-Set7 in the regulation of H4-
K20me3 was unexpected because this enzyme is clearly defi  ned 
as a methyltransferase that specifi  cally monomethylates histone 
H4-K20 (Couture et al., 2005; Xiao et al., 2005), whereas H4-
K20me3 was triggered by the Suv4-20h1 and Suv420h2 en-
zymes (Schotta et al., 2004). Importantly, the levels of Suv4-20h1 
and Suv420h2 are not altered in PR-Set7– depleted cells (un-
published data), indicating that the decrease in H4-K20me3 
is likely caused by loss of the monomethyl mark. This inter-
dependence between the lysine mono- and trimethylation state, 
as suggested here for histone H4-K20, has been previously de-
scribed for another mark of silent chromatin domains, histone 
H3-K9me (Peters et al., 2003; Schotta et al., 2004). In this case, 
the H3-K9 trimethylating enzymes appear to use an H3-K9 
monomethyl residue as their in vivo substrate (Peters et al., 
2003). Accordingly, knockout of the H3-K9 trimethylating en-
zymes in mouse embryonic stem cells resulted in a signifi  cant 
decrease in H3-K9me3 and, conversely, an increase in H3-
K9me1 (Peters et al., 2003, Schotta et al., 2004). Although the 
Error bars represent SD. (D) Distances between replicated tracks labeled with BrdU in shLuc and shPR7 U2OS cells, shPR7 U2OSSR cells, and shPR7 U2OS 
cells treated with caffeine for 5 h. The mean distances with SDs are indicated (right). (B and D) P < 0.0001 as determined by the nonparametric test of 
Mann-Whitney. (E) Cell cycle proﬁ  les of shPR7 U2OS cells untreated or treated with caffeine 3 d after shRNA expression. At the starting time point (top), 
cells were untreated (middle) or treated (bottom) with caffeine, and, 5 h later, they were labeled with BrdU before harvest and stained with an anti-BrdU antibody 
and 7AAD. Only histograms of DNA ﬂ  uorescence are shown.JCB • VOLUME 179 • NUMBER 7 • 2007  1422
Figure 5.  Growth-arrest functions of p53 avoid aberrant mitotic chromosome behavior after improper DNA replication in PR-Set7–depleted cells. (A) Cell 
cycle proﬁ  les of HNF and HNFE6 4 d after shLuc or shPR7 expression. Histograms of DNA content are shown. (B) Immunoﬂ  uorescence analysis of mitotic 
HNFE6 4 d after shLuc (a–c) or shPR7 (d–i) expression. DAPI staining (a, d, and g), H2A.X staining (b, e, and h), and phosphorylated histone H310 staining 
(c, g, and j) are shown. Note the abnormal DAPI staining in shPR7 HNFE6. (C) Chromosome spreads of shLuc (a) and shPR7 (b–d) HNFE6. (b and c) Exam-
ples of mitotic shPR7 HNFE6 showing improper chromosome condensation. (d1–4) Magniﬁ  cation of the selected areas from panel d showing chromosomal 
aberrations in shPR7 HNFE6. Bars: (B) 5 μm; (C) 2.5 μm. PR-SET7 FUNCTIONS IN DNA REPLICATION • TARDAT ET AL. 1423
Figure 6.  PR-Set7 regulates H4-K20 mono- and trimethylation, an essential function for proper S-phase progression and genomic stability. (A) Immunoblot 
analysis of the levels of PR-Set7, histone H4, H4-K20me1, H4-K20me2, and H4-K20me3 in U2OS and U2OSSR cells 3 d after shLuc or shPR7 expression. 
(B) Schematic structures of the shRNA-resistant wild-type (SR1), truncated (∆1–30, ∆37–50, ∆51–140, and ∆141–322), and mutated (R265G) PR-Set7 
recombinant proteins. (C) Cell cycle distribution of parental cells (bars 1 and 2) or cells synthesizing the indicated shRNA-resistant PR-Set7 recombinant 
proteins (bars 3–14) 3.5 d after shLuc (odd-numbered bars) or shPR7 (even-numbered bars) expression. The percentage of cells in each stage of the cell 
cycle is shown and was obtained by measuring BrdU incorporation (1-h pulse labeling before harvest) and DNA content with ﬂ  ow cytometry in three in-
dependent experiments. (D) Quantiﬁ  cation of γ-H2A.X–positive cells in parental U2OS cells and cells synthesizing the indicated shRNA-resistant PR-Set7 
recombinant proteins 3.5 d after shPR7 expression. The percentage of γ-H2A.X cells was obtained by counting 100 cells in three independent experi-
ments. No γ-H2A.X signal was detected in the different PR-Set7 recombinant–expressing cell lines untreated or treated with luciferase shRNA (not de-
picted). Error bars represent SD.JCB • VOLUME 179 • NUMBER 7 • 2007  1424
PR-Set7 loss of function phenotype described here provides the 
fi  rst evidence that this scenario might also apply to H4-K20me, 
it will be important to study the phenotype of the loss of func-
tion of Suv4-20h genes to fully address this question, a com-
pound model that is now available (Benetti et al., 2007).
PR-Set7 functions during DNA replication
An important fi  nding of our studies is that PR-Set7–depleted cells 
can initiate DNA replication, at least during early S phase, but 
then they fail to proceed properly with the elongation step of DNA 
replication. How might PR-Set7 ensure proper replica  tion fork 
progression? In Drosophila, the PR-Set7 orthologue suppresses 
position effect variegation (Nishioka et al., 2002; Karachentsev 
et al., 2005), raising the possibility that it functions as a transcrip-
tional repressor. Although we cannot exclude that mammalian 
PR-Set7 may indirectly promote replication fork progression by 
regulating gene expression, localization of the enzyme at sites of 
DNA synthesis (Fig. 1) and our results with synchronized cells 
(Fig. 2 D) support a model in which PR-Set7 would directly par-
ticipate in the replication machinery. Intriguingly, our results 
show that localization of PR-Set7 at replication foci is strongly 
enhanced upon proteasome inhibition (Fig. 1), suggesting a rapid 
exchange of the pool of PR-Set7 proteins associated with these 
foci during S phase. The biological signifi  cance of this proteasome-
mediated turnover of PR-Set7 is still unclear; however, our current 
hypothesis is that this might represent a novel and important regu-
latory step in the control of DNA replication. Among many other 
possible scenarios, this might be linked with rapid and local 
changes of chromatin structure that are necessary for the activation 
and displacement of replication forks along the DNA template 
(Nishitani et al., 2006; Senga et al., 2006).
Recruitment of a histone methyltransferase to sites of DNA 
synthesis is not unprecedented, as it has been observed for the 
histone H3-K9 methyltransferases G9a (Esteve et al., 2006) and 
SETDB1 (Sarraf and Stancheva, 2004). This is thought to con-
tribute to the restoration of H3-K9 methylation patterns on newly 
assembled chromatin behind the replication fork. A similar func-
tion of PR-Set7 in the maintenance of H4-K20 methylation pat-
terns during S phase would be consistent with our data and would 
notably explain why PR-Set7 inhibition causes an acute DNA 
replication stress. Indeed, structural analysis of nucleosomal par-
ticles revealed that the position of K20 within the N-terminal tail 
of histone H4 makes an interparticle contact between the histone 
H2A-H2B dimer and DNA (Davey et al., 2002), an observation 
that suggests that methylation of this lysine can directly affect the 
nucleosome structure. Furthermore, it has been recently shown 
that binding of the protein L3MBTL1 to nucleosomes is directly 
regulated by the specifi  c methylation state of H4-K20 (Trojer 
et al., 2007), which is thought to contribute to chromatin compac-
tion. Therefore, alterations in H4-K20 methylation could result 
in a rapid regulatory dead end for the packaging of nascent DNA 
into chromatin, thereby leading to the generation of DNA breaks, 
as we have observed in PR-Set7–depleted cells.
An alternative but not mutually exclusive possibility is that 
PR-Set7 may also modify other components of chromatin, in-
cluding the replication machinery itself, that are essential for 
proper replication fork progression and stability. For example, the 
acetyltransferase HBO1, which is required for S-phase initiation 
and fi  xing replication origins (Doyon et al., 2006), can acetylate 
histone H4 as well as replication proteins (Iizuka et al., 2006). 
Recently, PR-Set7 has been reported to monomethylate the tumor 
suppressor p53 at lysine 382, which represses p53 transcriptional 
activation on a subset of target genes (Shi et al., 2007). Impor-
tantly, inhibition of p53-K382me without affecting H4-K20me 
did not cause any growth defects in U2OS cells (Shi et al., 2007), 
suggesting that abnormal PR-Set7–mediated methylation of p53 
is not the prime cause of the replication defects described here. 
Other nonhistone targets of PR-Set7 have not been identifi  ed yet, 
and further work will be necessary to identify such targets. If they 
exist, it will be of great interest to determine whether their meth-
ylation plays a role in genome replication and stability.
Does PR-Set7 play a role in tumorigenesis?
The S phase of the cell cycle is a period of high vulnerability for 
the genome. Either intrinsic or external events can lead to the 
stalling of replication forks, which, if not managed properly, can 
have devastating consequences for the integrity of the genome. 
Indeed, there is now clear evidence that DNA damage during 
S phase can lead to genomic instability, thereby creating clones 
of cells that proliferate uncontrollably (Bartkova et al., 2005; 
Gorgoulis et al., 2005). Our fi  ndings that PR-Set7 catalytic activity 
ensures proper DNA replication and stability during S phase 
suggest that PR-Set7–mediated lysine methylation is a safe-
guarding posttranslational modifi  cation for the genome. This is 
particularly evident in cells defective for the tumor suppressor p53 
and depleted from PR-Set7, in which improper DNA replication 
and generation of DNA damage lead to aberrant mitotic chromo-
some behavior (Fig. 5), a hallmark of cancer cells (for review see 
Duesberg and Li, 2003). Given the importance of deregulated 
DNA replication in tumorigenesis (Bartkova et al., 2006; Di 
Micco et al., 2006) and that loss of H4-K20me3 patterns are ob-
served in almost all human cancers (Fraga et al., 2005), it will 
be interesting to explore whether PR-Set7 is a putative target for 
cellular transformation and contributes to tumor development.
Materials and methods
Cell lines and synchronization
U2OS cells and HNFs, either wild type or expressing the viral oncoprotein 
E6 (gift from J. Piette and V. Gire, Centre de Recherche en Biochimie Mac-
romoléculaire, Montpellier, France), were grown in DME with 10% FBS 
(Invitrogen) supplemented with penicillin and streptomycin. Synchronization of 
U2OS cells at the G1/S boundary was performed by a double thymidine 
block. Cells were ﬁ  rst blocked with 2.5 mM thymidine for 15 h, released for 
8 h, and then blocked again with 2.5 mM thymidine for 15 h. To control the 
efﬁ  ciency of synchronization, ﬂ  ow cytometry analysis was performed.
shRNA preparation and transfection
A human PR-Set7 shRNA directed against the PR-Set7 mRNA sequence 
G  A  T  G  C  A  A  C  T  A  G  A  G  A  G  A  C  A   (nucleotides 854–871) was checked against the 
human genome sequence to ensure that only the PR-Set7 mRNA would be tar-
geted. A ﬁ  reﬂ  y luciferase nonspeciﬁ  c control shRNA was used. The shRNA 
sequences were introduced into the puromycin retroviral vector RNAi Ready 
pSiren (BD Biosciences) according to the manufacturer’s instructions. Cells were 
infected with the corresponding retroviral particles as described previously 
(Le Cam et al., 2006) and were selected 24 h later in 10 μg/ml puromycin.
Mutagenesis and generation of PR-Set7SR cell lines
A hygromycin retroviral vector pMSCV was modiﬁ  ed to encode the HA ep-
itope tag downstream of the ATG, creating pMSCV-HA vector. The HA PR-SET7 FUNCTIONS IN DNA REPLICATION • TARDAT ET AL. 1425
epitope tag sequence is followed by an SpeI–BamH1 polylinker. Spe1–BamH1 
cDNA fragments encoding the different PR-Set7 truncations were cloned 
into pMSCV-HA vector. The PR-Set7SR constructs were prepared by intro-
ducing ﬁ  ve silent mutations into PR-Set7 cDNA as described previously (Ju-
lien and Herr, 2003). For stable PR-Set7SR expression, U2OS cells were 
infected as described previously (Le Cam et al., 2006) and selected with 
60 μg/ml hygromycin B.
Flow cytometry
Cells were incubated with 300 μM BrdU (Sigma-Aldrich) for 1 h, ﬁ  xed with 
a 70% ethanol solution, and permeabilized with 0.2% Triton X-100 for 10 min. 
Then, cells were treated with 0.2 N HCl before staining with mouse anti-
body to BrdU (1:30 diluted in PBS with 0.2% Tween 20 and 1% BSA; Becton 
Dickinson) for 1 h at room temperature followed by 1-h incubation with an 
FITC-conjugated antibody (1:300; BD Biosciences). DNA was then coun-
terstained by overnight incubation with 7-amino-actinomycin D (7AAD; 
1:50; Sigma-Aldrich) in the presence of RNase. Cell cycle proﬁ  les were 
analyzed by a ﬂ   ow cytometer (FACScan; Becton Dickinson) using Cell-
Quest software (Becton Dickinson).
Western blot analysis
For immunoblot analysis, cells washed with PBS were lysed in laemmli buf-
fer (for histones, acid extraction was performed according to the Abcam 
protocol). After measuring protein quantity by Bradford, equal amounts of 
protein were resolved by SDS-PAGE, transferred to a nitrocellulose mem-
brane (Whatman), and probed with one of the following antibodies: mouse 
antiphospho-ATM-Ser1981 (1:1,000; Cell Signaling Technology), rabbit 
antiphospho-ATR-Ser428 (1:1,000; Cell Signaling Technology), rabbit anti-
phospho-Chk1-Ser345 (1:1,000; Cell Signaling Technology), mouse anti-
Chk1 (1:1,000; gift from V. Gire), rabbit anti-p21 (1:500; gift from V. Dulik, 
Institut de Génétique Moléculaire, Montpellier, France), rabbit antiphospho-
p53-Ser15 (1:500; gift from V. Gire), mouse anti-p53 (1:1,000; gift from 
V. Gire), rabbit anti–PR-Set7 (1:1,000; Millipore), mouse anti–β-actin 
(1:20,000; Sigma-Aldrich), mouse antiphospho-H2A.X-Ser139 (1:1,000; 
Millipore), rabbit antiphospho-histone H3-Ser10 (1:1,000; Millipore), rab-
bit anti–H4-K20-1xMe, -2xMe, or -3xMe (1:1,000; Millipore), rabbit anti–
histone H4 (1:1,000; Millipore), and mouse anti-HA tag (12CA5; Cold Spring 
Harbor Laboratory). Membranes were then incubated with the appropriate 
HRP-conjugated secondary antibodies. The immunoreactive bands were 
detected by chemiluminescence (Thermo Fisher Scientiﬁ  c).
Immunoﬂ  uorescence
For immunoﬂ  uorescence, shRNA-infected cells grown on glass coverslips 
were ﬁ  xed in 3% PFA for 15 min, permeabilized with 0.2% Triton X-100 in 
PBS for 15 min, and blocked for 1 h with 1% BSA (Roche) at room temper-
ature. To visualize PR-Set7, cells on coverslips were pretreated with 15 μM 
MG132 for 1 h and incubated for 10 min at 4°C with a solution of PBS 
and 0.5% Triton X-100 before PFA ﬁ  xation. Incubation with primary anti-
bodies against PR-Set7 (1:600; Millipore), HA tag (12CA5; 1:500), phos-
pho-H2A.X-Ser139 (1:500; Millipore), phosphohistone H3-Ser10 (1:600; 
Millipore), proliferating cell nuclear antigen (1:500; gift from J. Piette), 
DNA polymerase ε (1:800; gift from D. Fischer, Institut de Génétique 
Moléculaire, Montpellier, France), and 53BP1 (1:500; Millipore) was con-
ducted at room temperature for 1 h. After washing, cells were incubated with 
AlexaFluor568- or 488-conjugated goat anti–mouse or goat anti–rabbit 
secondary antibodies (Invitrogen) for 1 h. Cells were ﬁ  nally stained with 
DAPI, and coverslips were mounted using Prolong Antifade (Invitrogen). 
Samples were examined at room temperature with a microscope (Imager.
Z1; Carl Zeiss, Inc.) equipped with a 63× NA 1.4 or 40× NA 1.25 oil 
immersion objective and an Apotome device (Carl Zeiss, Inc.). Pictures 
were captured using a camera (CoolSNAP HQ
2; Photometrics) interfaced 
with MetaMorph software 7.1 (MDS Analytical Technologies), and levels 
were adjusted with Photoshop 7 (Adobe). Digital sectioning images (Apo-
tome) were captured using Axiovision 4.6 software (Carl Zeiss, Inc.).
Chromosome spreading
3 d after shPR7 or shLuc expression, HNFE6 cells were incubated for 30 min 
with 10 μg/ml colchicine. After washing in PBS, cells were resuspended in 
a hypotonic solution of 75 μM KCl for 15 min at 37°C. They were then ﬁ  xed 
twice with a methanol/acetic acid buffer for 10 min at 4°C and spotted on 
frozen microscope glass slides. After drying, slides were stained with a solu-
tion of PBS and 0.1% Tween 20 containing Hoescht (1:10,000) mounted 
using Prolong Antifade, and images were captured at room temperature us-
ing an Imager.Z1 microscope with a 100× NA 1.4 oil immersion objective 
(Carl Zeiss, Inc.) equipped with a CoolSNAP HQ
2 camera interfaced with 
MetaMorph software 7.1. Levels were adjusted with Photoshop 7.0.
DNA combing
U2OS cells were pulse labeled for 15 min with 50 μM BrdU and were har-
vested. For IdU-CldU labeling experiments, cells were successively labeled 
for 1 h with 25 μM IdU and 200 μM CldU for 1 h. Nuclei (from  2.5 × 
10
4 cells) were embedded in agarose plugs, stained with YOYO-1 (Invitro-
gen), and resuspended in 50 mM MES, pH 5.6, after digestion of the plugs 
with agarase (Roche). Then, DNA combing was performed as described 
previously (Michalet et al., 1997). In brief, combed DNA ﬁ  bers were de-
natured for 25 min with 0.2 N NaOH, and BrdU and CldU were detected 
with a rat anti-BrdU antibody (clone BU-75; Sera Laboratory) and a second-
ary antibody coupled to AlexaFluor488 (Invitrogen). IdU was detected with 
a mouse monoclonal anti-IdU antibody (clone B44; Becton Dickinson) and 
a secondary antibody coupled with AlexaFluor546 (Invitrogen). DNA mol-
ecules were counterstained as previously described (Pasero et al., 2002) 
with an antiguanosine antibody (Argene) and an anti–mouse IgG coupled 
to AlexaFluor546 (Invitrogen). DNA ﬁ  bers were examined, and images 
were captured at room temperature using a microscope (DMRX; Leica) with 
a 40× NA 1.25 oil immersion objective (Leica) and equipped with a Cool-
SNAP FX camera interfaced with MetaMorph software 7.1. Levels were 
adjusted with Photoshop 7.0. Replicated track sizes were measured with 
MetaMorph using adenovirus DNA molecules as a size standard (one pixel = 
680 bp). Fork speed was calculated by dividing track sizes by labeling 
time, and the nonparametric test of Mann-Whitney was used.
Comet assay
DNA break repair was assayed by alkaline single-cell agarose gel electro-
phoresis essentially as described previously (Murr et al., 2006). In brief, 
cells were infected with shRNA luc (control) or shRNA PR-Set7, harvested 
( 10
5 per pellet) 5 d after infection, mixed with low-gelling temperature 
agarose (type VII; Sigma-Aldrich), and layered onto agarose-coated glass 
slides. Slides were maintained in the dark at 4°C to gel and were sub-
merged in lysis buffer (2.5 M NaCl, 0.1 M EDTA, 10 mM Trizma base, 1% 
Triton X-100, and 10% DMSO) for at least 1.5 h. After washing with Tris 
buffer, slides were incubated for 1 h in alkaline electrophoresis buffer (300 
mM NaOH and 1 mM EDTA, pH 10) or in neutral electrophoresis buffer 
(300 mM sodium acetate, 100 mM Tris-HCl, and 1% DMSO, pH 8.3). 
Slides were then subjected to electrophoresis for  40 min at 25 V, air 
dried, neutralized, and stained with 30 μl ethidium bromide (20 μg/ml
–1). 
Mean comet tail moment was scored for 50 cells/slide by using Comet Imager 
1.2.10 software (MetaSystems Inc.).
Online supplemental material
Fig. S1 shows the cell cycle distribution of PR-Set7 in U2OS and normal 
ﬁ  broblasts (A) and in the nuclear localization of HA epitope–tagged PR-
Set7 in U2OS cells treated for 1 h with proteasome inhibitor MG132 (B). 
Fig. S2 shows representative DNA combing pictures in shLuc and shPR7 
U2OS cells. Fig. S3 shows 53BP1 localization at spontaneous DNA dam-
age foci in shPR7-depleted U2OS cells and quantiﬁ  cation of shPR7 U2OS 
cells displaying 53BP1 foci after ionizing radiation. Fig. S4 shows the 
impact of PR-Set7 depletion in proliferation rates and H4-K20me status of 
HeLa cells. Online supplemental material is available at http://www.jcb
.org/cgi/content/full/jcb.200706179/DC1.
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